Cargando…
Evaluation of blood gene expression levels in facioscapulohumeral muscular dystrophy patients
Facioscapulohumeral muscular dystrophy (FSHD) is caused by the expression of DUX4 in skeletal muscles. A number of therapeutic approaches are being developed to antagonize the events preceding and following DUX4 expression that leads to muscular dystrophy. Currently, the possibility to evaluate trea...
Autores principales: | Signorelli, M., Mason, A. G., Mul, K., Evangelista, T., Mei, H., Voermans, N., Tapscott, S. J., Tsonaka, R., van Engelen, B. G. M., van der Maarel, S. M., Spitali, P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567883/ https://www.ncbi.nlm.nih.gov/pubmed/33067535 http://dx.doi.org/10.1038/s41598-020-74687-5 |
Ejemplares similares
-
Characterizing the face in facioscapulohumeral muscular dystrophy
por: Loonen, T. G. J., et al.
Publicado: (2020) -
Consequences of epigenetic derepression in facioscapulohumeral muscular dystrophy
por: Greco, Anna, et al.
Publicado: (2020) -
The socioeconomic burden of facioscapulohumeral muscular dystrophy
por: Blokhuis, Anna M., et al.
Publicado: (2021) -
Quantitative muscle MRI and ultrasound for facioscapulohumeral muscular dystrophy: complementary imaging biomarkers
por: Mul, Karlien, et al.
Publicado: (2018) -
Immunohistochemical Characterization of FacioscapulohumeralMuscular Dystrophy Muscle Biopsies
por: Statland, Jeffrey M., et al.
Publicado: (2015)